Patents by Inventor Jean-Baptiste Marchand
Jean-Baptiste Marchand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240374719Abstract: The present invention generally relates to a combination of an oncolytic virus capable of expressing a first antibody molecule that specifically binds to CTLA-4; and a second antibody molecule that specifically binds to PD-1 and/or PD-L1 and uses thereof in the treatment of cancer.Type: ApplicationFiled: September 21, 2022Publication date: November 14, 2024Applicants: BIOINVENT INTERNATIONAL AB, TRANSGENE SAInventors: Björn FRENDÉUS, Matilda REHN, Monika SEMMRICH, Linda MÅRTENSSON, Jean-Baptiste MARCHAND
-
Patent number: 11969462Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of the personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing the target regions from the extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from the tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy.Type: GrantFiled: June 21, 2018Date of Patent: April 30, 2024Assignee: TransgeneInventors: Kaïdre Bendjama, Nathalie Silvestre, Jean-Baptiste Marchand, Benoît Grellier
-
Patent number: 11779619Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: GrantFiled: December 23, 2019Date of Patent: October 10, 2023Assignee: Transgene SAInventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Publication number: 20230277639Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing said target regions from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy.Type: ApplicationFiled: April 13, 2023Publication date: September 7, 2023Applicant: TransgeneInventors: Kaïdre Bendjama, Nathalie Silvestre, Jean-Baptiste Marchand, Benoît Grellier
-
Publication number: 20220056481Abstract: The present invention is in the field of oncolytic viruses. The invention provides new poxviruses which are engineered to be defective for the function encoded by the M2L locus (i.e., m2 function). Such poxviruses lack a functional m2 binding activity to at least one or both of CD80 and CD86 co-stimulatory antigens. Said oncolytic poxviruses are preferably vaccinia virus having a total or partial deletion of the M2L locus. The present invention also relates to cells and compositions comprising such poxviruses and their use for treating proliferative diseases such as cancers and for preventing diseases (vaccination, especially in veterinary field). More precisely, the invention provides an alternative to the existing oncolytic viruses which are largely used in virotherapy. The m2-defective poxviruses are particularly useful for the expression of immunomodulatory polypeptides such as anti-CTLA-4 antibodies with the purposes of stimulating or improve immune response.Type: ApplicationFiled: December 27, 2019Publication date: February 24, 2022Applicant: TRANSGENEInventors: Patricia KLEINPETER, Jean-Baptiste MARCHAND, Christelle REMY, Doris SCHMITT
-
Publication number: 20220041723Abstract: Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.Type: ApplicationFiled: September 3, 2019Publication date: February 10, 2022Inventors: Björn FRENDÉUS, Ingrid TEIGE, Monika SEMMRICH, Linda MÅRTENSSON, Petra HOLMKVIST, Jean-Baptiste MARCHAND, Nathalie SILVESTRE
-
Patent number: 10765731Abstract: The present invention relates generally to novel immunogenic combinations comprising or encoding at least two heterooligomeric mycobacterial antigens and preferably a fusion polypeptide comprising said two heterooligomeric mycobacterial antigens, where the mycobacterial antigens are selected from the group of Esx, PE and PPE antigens of a Mycobacterium species, particularly a Mycobacterium of the tuberculosis complex such as Mycobacterium tuberculosis (Mtb). The present invention also relates to vectors, host cells and compositions comprising or encoding said immunogenic combination as well as to methods for expressing and producing it. The present invention also relates to methods of using said immunogenic combination, fusion polypeptide, vector, host cell, composition particularly for inducing or stimulating an immune response with the goal of providing a protective response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.Type: GrantFiled: January 9, 2015Date of Patent: September 8, 2020Assignee: TRANSGENE SAInventors: Jean-Baptiste Marchand, Nathalie Silvestre, François Penin
-
Publication number: 20200197457Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: ApplicationFiled: December 23, 2019Publication date: June 25, 2020Applicant: Transgene S.A.Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Patent number: 10662414Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: January 25, 2019Date of Patent: May 26, 2020Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20200138923Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably the entire coding regions of the genome (exome), c) sequencing said target regions (e.g. the exome) from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine.Type: ApplicationFiled: June 21, 2018Publication date: May 7, 2020Applicant: TransgeneInventors: Kaïdre Bendjama, Nathalie Silvestre, Jean-Baptiste Marchand, Benoît Grellier
-
Patent number: 10555981Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: GrantFiled: July 16, 2015Date of Patent: February 11, 2020Assignee: Transgene S.A.Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Patent number: 10357555Abstract: The present invention relates generally to immunogenic combinations comprising at least five antigens of a Mycobacterium species as well as fusion thereof and nucleic acid molecules encoding such combined antigens and fusion. The present invention also relates to nucleic acid molecules, vectors, host cells and compositions comprising or encoding said combinations of mycobacterial antigens and fusion polypeptides as well as to methods for recombinantly producing them. The present invention also relates to methods of using said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions particularly for inducing or stimulating an immune response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.Type: GrantFiled: July 10, 2013Date of Patent: July 23, 2019Assignee: TRANSGENE SAInventors: Emmanuel Tupin, Romain Micol, Charles Antoine Coupet, Geneviève Inchaupse, Marie Gouanvic, Nathalie Silvestre, Jean-Baptiste Marchand, Cécile Beny
-
Publication number: 20190144840Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: ApplicationFiled: January 25, 2019Publication date: May 16, 2019Applicant: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Patent number: 10190105Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: December 5, 2016Date of Patent: January 29, 2019Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Patent number: 9982055Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.Type: GrantFiled: July 19, 2016Date of Patent: May 29, 2018Assignee: TRANSGENE S.A.Inventors: Hélène Haegel, Christine Thioudellet, Michel Geist, Benoit Grellier, Jean-Baptiste Marchand
-
Publication number: 20170157188Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: ApplicationFiled: July 16, 2015Publication date: June 8, 2017Applicant: Transgene S.A.Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Publication number: 20170145392Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: ApplicationFiled: December 5, 2016Publication date: May 25, 2017Applicant: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20170002081Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.Type: ApplicationFiled: July 19, 2016Publication date: January 5, 2017Inventors: Hélène HAEGEL, Christine Thioudellet, Michel Geist, Benoit Grellier, Jean-Baptiste Marchand
-
Patent number: 9512412Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: July 12, 2012Date of Patent: December 6, 2016Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20160331823Abstract: The present invention relates generally to novel immunogenic combinations comprising or encoding at least two heterooligomeric mycobacterial antigens and preferably a fusion polypeptide comprising said two heterooligomeric mycobacterial antigens, where the mycobacterial antigens are selected from the group of Esx, PE and PPE antigens of a Mycobacterium species, particularly a Mycobacterium of the tuberculosis complex such as Mycobacterium tuberculosis (Mtb). The present invention also relates to vectors, host cells and compositions comprising or encoding said immunogenic combination as well as to methods for expressing and producing it. The present invention also relates to methods of using said immunogenic combination, fusion polypeptide, vector, host cell, composition particularly for inducing or stimulating an immune response with the goal of providing a protective response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.Type: ApplicationFiled: January 9, 2015Publication date: November 17, 2016Applicant: TRANSGENE SAInventors: Jean-Baptiste MARCHAND, Nathalie SILVESTTRE, Francois PENIN